Stream
Stories
-
FDA releases draft guidance on U.S.-origin statements for seafood labeling
The notice was published on October 27, 2026. It will provide examples of labeling statements that the FDA would consider truthful and not misleading once finalized.
-
FDA determines PEPCID RPD famotidine tablets not withdrawn for safety or effectiveness
The agency decided that the 20 mg and 40 mg orally disintegrating tablets were not removed from sale. This determination will allow FDA to approve abbreviated new drug applications for these products if all other legal and regulatory requirements are met.
-
Amgen APPOINTS David W. Gibbs to board of directors
The appointment is effective immediately and Gibbs will serve on the Audit Committee and Compensation and Management Development Committee. The Board will have 13 directors, 12 of whom are independent.
-
FDA approves talazoparib with enzalutamide for metastatic prostate cancer
On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations, as detected by an FDA-authorized test. The TALAPRO-3 trial showed median radiographic progression-free survival not reached (95% CI: NR, NR) versus 45.8 months (95% CI: 37.7, NR) with a hazard ratio of 0.48 [95% CI: 0.36, 0.65]; p<0.0001.
-
Abbott launches whole-genome sequencing Oncodetect MRD test
Abbott announced the commercial availability of its next-generation Oncodetect MRD test, a personalized, tumor-informed, whole-genome sequencing test that tracks up to 5,000 patient-specific variants with a limit of detection below one part per million. The company said the test could be used for patients with solid tumors.
-
Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer
The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll 1050 participants and begin on November 20, 2026. It compares HRS-6209 plus letrozole with dalpciclib or palbociclib plus aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment.
-
UNION trial shows 3-year event-free survival 91·3% vs 77·4%
In a prespecified interim analysis of 231 patients, the experimental group achieved a 3-year investigator-assessed event-free survival rate of 91·3% compared with 77·4% in the standard-of-care group (log-rank p=0·0029). Treatment-related serious adverse events occurred in 19% of experimental patients versus 13% of standard-of-care patients.
-
Pembrolizumab plus chemotherapy prolongs PFS versus monotherapy in high-PD-L1 NSCLC
In the PERSEE phase III trial, 321 patients with stage IV or unresectable stage III NSCLC and PD-L1 ≥50% were randomized to pembrolizumab alone or with platinum-based chemotherapy. Median progression-free survival was 16.1 months with combination versus 6.9 months with monotherapy (HR 0.56, 95% CI 0.43-0.74; P<0.001).
-
PRABITAS trial shows 14-day trifluridine-tipiracil plus bevacizumab non-inferior to 28-day schedule
The authors reported that the 14-day schedule achieved a median overall survival of 11·3 months versus 10·3 months for the 28-day schedule, with a stratified hazard ratio of 0·93 (95% CI 0·80-1·08). Neutropenia grade 3 or worse was reduced by 25 percentage points (13% vs 39%) and anorexia grade 2 or worse by 11 percentage points (15% vs 26%).
-
Nivolumab plus ipilimumab shows significant OS benefit versus NIVO and chemotherapy
The authors reported a hazard ratio of 0.61 versus NIVO across all lines and 0.37 versus chemotherapy in first-line therapy, with 95% confidence intervals of 0.46-0.82 and 0.24-0.57 respectively. Grade 3/4 treatment-related adverse events occurred in 22% of NIVO+IPI patients versus 14% of NIVO patients, with no new safety concerns.
-
Lilly presents durable first-line activity of olomorasib in KRAS G12C-mutant NSCLC at ESMO 2026
Lilly reported that olomorasib plus pembrolizumab without chemotherapy achieved durable efficacy, with median progression-free survival not yet reached after a median follow-up of 20.7 months. In a separate rapid oral presentation, the combination with chemoimmunotherapy yielded a 62% investigator-assessed overall response rate and a median duration of response of 14.5 months.
-
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143
Johnson & Johnson said that in a Phase 1 study of JNJ-6143, 75 percent (12 of 16) of patients with measurable disease achieved a confirmed complete or partial response. The company also noted that 77 percent of patients at the 50-mg dose had a confirmed PSA reduction of at least 50 percent, with 48 percent achieving reductions of at least 90 percent.